Legend Biotech enters the final trading days of August with a contradictory setup: short sellers are unwinding positions rapidly, yet the stock fell 9% on the week to $19.88 while analysts slashed targets following a difficult earnings print.
The short interest story is the most dynamic element right now. Bears have been covering aggressively — SI as a percentage of the free float dropped from roughly 10.7% to 9.1% over the past week, a 14% reduction in borrowed shares outstanding. Zoom out one month, however, and the picture flips: short interest is still 24% higher than it was thirty days ago, meaning last week's covering only partially reverses a significant August build that peaked around August 11. Borrow conditions tell a similarly mixed tale. Cost to borrow is negligible at 0.64%, barely changed on the week, and far below anything that would create squeeze pressure. Availability has loosened meaningfully — back to roughly 59% from a trough near 24% on August 11 — suggesting the lending market is no longer stressed and shorts can still establish or maintain positions without difficulty. The ORTEX short score, at 74.7, has drifted lower over the past two weeks from a high above 77, consistent with the covering trend, but remains elevated in an absolute sense.
Options positioning reinforces the broadly constructive lean. The put/call ratio hit 0.36 on Friday — a 52-week low — and runs about one standard deviation its 20-day average of 0.40. That is the least defensive options posture LEGN has carried all year, with call open interest heavily dominating. The divergence between a still-elevated short interest base and an unusually call-heavy options book is the week's central tension: one cohort is covering, another is reaching for upside. Neither is a consensus.
The Street itself is fractured in a way that rarely resolves quickly. Analysts responded to the August 12 Q2 results with a wave of target cuts. Oppenheimer delivered the harshest verdict, downgrading to Perform and slashing its target from $75 to $40. Morgan Stanley held its Overweight but moved only marginally higher, to $49. TD Cowen kept its Hold and trimmed to $24. Barclays and RBC both stayed constructive but trimmed modestly. The mean target now sits at $49.25, implying roughly 150% upside from the current $19.88 — a gap that size almost always reflects deep disagreement rather than consensus conviction. The bull case centres on Carvykti's $5 billion-plus peak sales potential and the Janssen/J&J commercial partnership. The bear case points to lentiviral manufacturing concerns, SEC compliance questions that surfaced earlier in the year, and a stock that, even after recovering 4% over the past month, remains deeply depressed relative to where most target prices are set. Forward earnings estimates are trending higher year-on-year — the 12-month forward EPS improvement factor scores in the 73rd percentile — but near-term EPS momentum scores are weak, in the low-to-mid twenties, reflecting the recent miss.
Institutional positioning adds texture. FMR (Fidelity) filed a 13G/A on August 6 showing a stake that rose from 13.1% to 15% of the class — a meaningful addition from one of biotech's most closely watched active managers. Goldman Sachs added over 2 million shares in Q2, ending the period with roughly 1.9% of the company. Deerfield, a specialist healthcare fund, added 450,000 shares. These moves run counter to the recent short build, and they suggest at least some institutional buyers were using the sell-off as an entry point. Genscript Biotech, the founding parent, remains the dominant holder at 45% of shares, limiting the true tradeable float and amplifying the impact of any positioning shifts.
The next catalyst is Q3 earnings, currently scheduled for November 12. Between now and then, Carvykti commercial data — quarterly net sales updates from Janssen — and any manufacturing capacity announcements will be the key variables that determine whether the short covering of the past week continues or reverses back toward the August highs.
See the live data behind this article on ORTEX.
Open LEGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
